Movement Alert｜Alibaba Health Rises 3.57% at Open, Innovative Drug First-Launch Platform Effect Continues to Ferment

Market Focus

Jul 02

On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.

On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first domestically developed high-selectivity URAT1 inhibitor for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taitutuo (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health on June 29. The simultaneous selection of Alibaba Health as the online exclusive first-launch channel by two blockbuster innovative drugs validated the company's channel value and digital service capabilities in innovative drug commercialization, reinforcing its strategic positioning as a first-launch platform for new specialty drugs.

Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. Multiple investment banks including Bank of America and Jefferies maintain Buy ratings on the stock, citing long-term industry digitalization opportunities and the company's integrated B2C and O2O positioning.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1169739616"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169739616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169739616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169739616","market":"us","top_or_hot":-1,"title":"Movement Alert｜Alibaba Health Rises 3.57% at Open, Innovative Drug First-Launch Platform Effect Continues to Ferment","media":"Market Focus","content":"<p><p>On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.</p><p>On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first domestically developed high-selectivity URAT1 inhibitor for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taitutuo (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health on June 29. The simultaneous selection of Alibaba Health as the online exclusive first-launch channel by two blockbuster innovative drugs validated the company's channel value and digital service capabilities in innovative drug commercialization, reinforcing its strategic positioning as a first-launch platform for new specialty drugs.</p><p>Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. Multiple investment banks including Bank of America and Jefferies maintain Buy ratings on the stock, citing long-term industry digitalization opportunities and the company's integrated B2C and O2O positioning.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alibaba Health Rises 3.57% at Open, Innovative Drug First-Launch Platform Effect Continues to Ferment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alibaba Health Rises 3.57% at Open, Innovative Drug First-Launch Platform Effect Continues to Ferment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 09:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.</p><p>On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first domestically developed high-selectivity URAT1 inhibitor for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taitutuo (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health on June 29. The simultaneous selection of Alibaba Health as the online exclusive first-launch channel by two blockbuster innovative drugs validated the company's channel value and digital service capabilities in innovative drug commercialization, reinforcing its strategic positioning as a first-launch platform for new specialty drugs.</p><p>Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. Multiple investment banks including Bank of America and Jefferies maintain Buy ratings on the stock, citing long-term industry digitalization opportunities and the company's integrated B2C and O2O positioning.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00241","symbol_name":"阿里健康","start_time":0,"source_url":"","article_id":"1169739616","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169739616","pubTimestamp":1782955385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00241":"阿里健康"},"translate_title":"运动快讯|阿里巴巴-SW健康开盘涨3.57%创新药首发平台效应持续发酵","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first domestically developed high-selectivity URAT1 inhibitor for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taitutuo (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health on June 29. The simultaneous selection of Alibaba Health as the online exclusive first-launch channel by two blockbuster innovative drugs validated the company's channel value and digital service capabilities in innovative drug commercialization, reinforcing its strategic positioning as a first-launch platform for new specialty drugs.Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. Multiple investment banks including Bank of America and Jefferies maintain Buy ratings on the stock, citing long-term industry digitalization opportunities and the company's integrated B2C and O2O positioning.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}